Telix Pharmaceuticals Limited (TLX) Reports FY results; offers guidance

Telix Pharmaceuticals Limited (NASDAQ: TLX) reported FY Revenue at AU$783.2 million.

GUIDANCE:

Telix Pharmaceuticals Limited sees FY2025 revenue of $770-800 million, versus the consensus of $748.3 million.

For earnings history and earnings-related data on Telix Pharmaceuticals Limited (TLX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00